Mark Velleca
Chief Executive Officer bei BLACK DIAMOND THERAPEUTICS, INC.
Vermögen: 736 987 $ am 31.03.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
David Epstein | M | 65 | 10 Jahre | |
Norman Sharpless | M | 57 | 10 Jahre | |
Jack Bailey | M | 59 | 4 Jahre | |
Monica Thomas | F | - | 1 Jahre | |
Anil K. Goyal | M | 59 |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology IMMvention Therapeutix, Inc. is an American biotechnology company that develops therapies. The company was founded by Jenny Ting and the CEO is Anil K. Goyal. | - |
Szabolcs Nagy | M | 35 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The private company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | 11 Jahre |
Garry Nicholson | M | 69 | 6 Jahre | |
Aravind Asokan | M | - |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | - |
Elizabeth Buck | M | 49 | 10 Jahre | |
Kristof Zsolt Szalay | M | 38 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The private company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | 11 Jahre |
Ari Helenius | M | - |
Yale University
| 41 Jahre |
Jacks Lee | M | 60 | 2 Jahre | |
Ali Behbahani | M | 47 | 6 Jahre | |
Cynthia Flowers | F | 64 | 6 Jahre | |
Garry Menzel | M | 59 | 10 Jahre | |
Terry Murdock | M | 64 | 7 Jahre | |
Kapil Dhingra | M | 64 | 3 Jahre | |
Radha Kuppalli | F | - |
Yale University
| 16 Jahre |
Samarth Kulkarni | M | 45 | 5 Jahre | |
Lei Zhang | M | 51 |
Yale University
| - |
Erika Jones | F | 39 | 5 Jahre | |
Rosemarie Loffredo | F | - |
The Leukemia & Lymphoma Society, Inc.
The Leukemia & Lymphoma Society, Inc. Miscellaneous Commercial ServicesCommercial Services The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY. | 11 Jahre |
Alicia Secor | F | 62 | 3 Jahre | |
Richard Foster | M | 82 |
Yale University
| - |
Jenny Ting | M | - |
IMMvention Therapeutix, Inc.
IMMvention Therapeutix, Inc. BiotechnologyHealth Technology IMMvention Therapeutix, Inc. is an American biotechnology company that develops therapies. The company was founded by Jenny Ting and the CEO is Anil K. Goyal. | - |
Fang Ni | M | 37 | 4 Jahre | |
William C. Roberts | M | 54 | 3 Jahre | |
Greg P. Bertenshaw | M | - |
BioMarker Strategies LLC
BioMarker Strategies LLC Pharmaceuticals: GenericHealth Technology BioMarker Strategies LLC develops medicines for cancer. It provides cancer diagnostics system for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies. The company was founded by Scott Allocco, Kathleen Murphy and Douglas P. Clark in May 2006 and is headquartered in Rockville, MD. | 13 Jahre |
Richard Levin | M | 77 |
Yale University
| 31 Jahre |
Daniel Veres | M | 35 |
Turbine Hálózatelemzo Kutatási Fejlesztési Kft.
Turbine Hálózatelemzo Kutatási Fejlesztési Kft. Packaged SoftwareTechnology Services Part of Turbine Simulated Cell Technologies Ltd., Turbine Hálózatelemzo Kutatási Fejlesztési Kft. The Hungarian company specializes in unlocking therapies with simulated cells™. Turbine computationally simulates tumor cell behavior in patients to understand the complex mechanisms driving the disease. The simulations can reveal the right modality and combination approach to treat even the most resistant cancers. The private company's platform enables the simulation of drug-like effects from compounds that may not exist yet, on cells potentially unavailable for lab-based testing, like those of high unmet need cancer patients. is a Budapest-based company founded in 2013 by Daniel Veres, Szabolcs Nagy, and Kristof Zsolt Szalay. Szabolcs Nagy has been the CEO since 2013. | 11 Jahre |
Brent Hatzis-Schoch | M | 59 | 5 Jahre | |
Glenn Muir | M | 65 | 9 Jahre | |
Liane E Philpotts | M | - |
Yale University
| - |
Dianne Witte | F | - |
Yale University
| - |
Vincent Marchesi | M | 88 |
Yale University
| 51 Jahre |
William Kennard | M | 67 |
Yale University
| 10 Jahre |
Hyuk-Jeen Suh | M | - |
Yale University
| 4 Jahre |
E. Jonathan Soderstrom | M | 69 |
Yale University
| - |
Scott Nicholas Gettinger | M | - |
Yale University
| - |
David Sze | M | 58 |
Yale University
| - |
John Puziss | M | - |
Yale University
| 23 Jahre |
James Timberlake | M | - |
Yale University
| - |
Sandra A. Carson | M | 70 |
Yale University
| - |
Sally E. Shaywitz | M | - |
Yale University
| - |
William Sessa | M | - |
Yale University
| - |
Harvey J. Berger | M | 74 |
Yale University
| - |
Lauren Zucker | F | 54 |
Yale University
| 13 Jahre |
Michael Roemer | M | 96 |
Yale University
| - |
David I. Scheer | M | 71 |
Yale University
| - |
George Baker | M | 81 |
Yale University
| - |
Alan G. Schwartz | M | 84 |
Yale University
| 37 Jahre |
Roland Hernandez | M | 65 |
Yale University
| - |
Donald M. Engelman | M | 83 |
Yale University
| 45 Jahre |
Joseph F. Renzulli | M | - |
Yale University
| - |
William Wright | M | 64 |
Yale University
| - |
Rishay Patel | M | - |
Yale University
| 3 Jahre |
James Tananbaum | M | 60 |
Yale University
| - |
Martha Woodcock | F | - |
Yale University
| - |
Melanie Ginter | F | - |
Yale University
| - |
Christopher di Bonaventura | M | - |
Yale University
| - |
Jeff Miller | M | 75 |
Yale University
| - |
Bruce E. Wexler | M | - |
Yale University
| - |
John Rice | M | 57 |
Yale University
| - |
Daniel Abadi | M | - |
Yale University
| - |
Peter R. Crane | M | - |
Yale University
| - |
Paul Bracken | M | - |
Yale University
| - |
Patricia Sue Fitzsimons | M | - |
Yale University
| - |
Elyse G. Seltzer | M | 59 |
Yale University
| - |
Vincent Pieribone | M | - |
Yale University
| - |
Jonathan R. Macey | M | 68 |
Yale University
| - |
Martin H. Schultz | M | - |
Yale University
| - |
Thomas A. Steitz | M | - |
Yale University
| - |
Frances G. Beinecke | F | - |
Yale University
| - |
Kenneth V. Schwartz | M | - |
Yale University
| - |
Viswanathan Vinay | M | - |
Yale University
| - |
Amy Wrzesniewski | M | - |
Yale University
| - |
Stephen L. Carter | M | - |
Yale University
| - |
James Gustave Speth | M | - |
Yale University
| - |
Leo M. Cooney | M | - |
Yale University
| - |
Stephen S. Roach | M | 79 |
Yale University
| - |
William L. Jorgensen | M | - |
Yale University
| - |
Edward L. Snyder | M | 77 |
Yale University
| - |
Kyle Pruett | M | - |
Yale University
| - |
Joseph P. Schlessinger | M | 79 |
Yale University
| - |
Yung Chi Cheng | M | - |
Yale University
| - |
Steven Dworetzky | M | - |
Yale University
| - |
Michael Warren | M | 56 |
Yale University
| - |
John Deno Geanakoplos | M | 68 |
Yale University
| 38 Jahre |
Susan Medak | F | - |
Yale University
| - |
Steve Blum | M | 72 |
Yale University
| - |
Frank Slack | M | - |
Yale University
| - |
J Anthony Sheldon | M | - |
Yale University
| - |
Sean T. Dixon | M | - |
Yale University
| - |
Philip Himberg | M | - |
Yale University
| - |
Tom Glocer | M | 63 |
Yale University
| - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jay C. Strum | M | - | 11 Jahre | |
Troy Wilson | M | 55 |
Intellikine LLC
Intellikine LLC Pharmaceuticals: MajorHealth Technology Intellikine LLC develops and manufactures small molecule drugs for the treatment of cancer. The company focused on the development of potent, selective small molecule inhibitors of the PI3K/Akt/mTOR pathway for the treatment of cancer, inflammation and autoimmune disorders. Intellikine was founded on May 2nd, 2007 and is headquartered in La Jolla, CA. | 5 Jahre |
Christy Shaffer | M | 66 | 6 Jahre | |
Seth A. Rudnick | M | 75 | 7 Jahre | |
Jennifer Moses | F | 49 | - |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 97 | 97,00% |
Ungarn | 3 | 3,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Mark Velleca
- Persönliches Netzwerk